Michael G Ison

Grants

Grants per year

2006 2024

• 14 Active
• 40 Finished

Grants per year

Search results

• Active

  Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients

  Ison, M. G. & Roitberg-Tambur, A.

  Vanderbilt University Medical Center, National Institute of Allergy and Infectious Diseases

  9/1/20 → 6/30/21

  Project: Research project

• ACTIV-1 IM: Randomized Master Protocol for Immune Modulators for Treating COVID-19

  Ison, M. G.

  Duke University, Biomedical Advanced Research and Development Authority

  8/17/20 → 8/16/21

  Project: Research project

• Administrative Supplement to Real-time Wideband Cardiac MRI for Patients with a Cardiac Implantable Electronic Device

  Ison, M. G., Kim, D., Lee, D. C., Markl, M., Ragin, A. B., Yancy, C. W. & Allen, B. D.

  National Heart, Lung, and Blood Institute

  8/14/20 → 7/31/21

  Project: Research project

  • Respiration
  • Galectin 3
  • Equipment and Supplies
  • Organized Financing
  • Industry

• Protocol No. P10934-CMVPS-CSP-01: Clinical Performance of the Aptima® CMV Quant Assay on the Panther® System

  Ison, M. G.

  Hologic, Inc.

  5/2/19 → 5/2/22

  Project: Research project

• [U19] Integrated Genomics of Mucosal Infections: Viral Diversity and Pathogenicity in Mucosal Respiratory and Gastrointestinal Disease

  Ison, M. G.

  Baylor College of Medicine, National Institute of Allergy and Infectious Diseases

  4/15/19 → 3/31/24

  Project: Research project

  • Gastrointestinal Diseases
  • Genomics
  • Virulence
  • Communicable Diseases
  • Virus Diseases

• Prot. CP40617 - A Phase III, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Assess the Efficacy and Safety of Baloxavir Marboxil in Combination with a Neuraminidase Inhibitor versus a Neuraminidase Inhibitor Alone in Hospitalized Patien

  Ison, M. G.

  Syneos Health, Inc., Genentech, Inc.

  2/22/19 → 2/22/22

  Project: Research project

• Prot. Number IA-001: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection

  Ison, M. G.

  SGS North America Inc., Cangene Corporation

  12/15/17 → 12/15/20

  Project: Research project

• AIC316-03-II-01 A Randomized, Open Label, Multi-Center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-Resistant Mucocutaneous HSV Infections in Immunocompromised Adults (PRIOH-1)

  Ison, M. G.

  Medpace, Inc., AiCuris Anti-infective Cures GmbH

  12/1/17 → 12/1/22

  Project: Research project

• Protocol 9766-MA-3034 - Observational Disease Registry of Patients Treated with Systemic Mold-Active Triazoles

  Ison, M. G.

  inVentiv Health Clinical, Astellas Pharma Global Development, Inc.

  4/7/17 → 4/7/22

  Project: Research project

• PROTOCOL: SHP620-303 A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infection

  Ison, M. G.

  PPD Development, Shire ViroPharma Incorporated

  3/24/17 → 3/24/21

  Project: Research project

• Phase II Multi-Center, Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematpoietic Stem Cell and Solid Organ Transplant Recipients

  Angarone, M. P., Ison, M. G. & Zhao, L.

  National Institute of Allergy and Infectious Diseases

  7/1/16 → 6/30/21

  Project: Research project

  • nitazoxanide
  • Norovirus
  • Double-Blind Method
  • Transplant Recipients
  • Stem Cells

• Fixed Price Patient Care Costs

  Ison, M. G.

  National Institute of Allergy and Infectious Diseases

  7/1/16 → 6/30/21

  Project: Research project

  • nitazoxanide
  • Norovirus
  • Patient Care
  • Costs and Cost Analysis
  • Transplants

• Option One of Phase II Multi-Center, Prospective, Randomized, Double-Blind Study of Nitazoxanide in Acute and Chronic Norovirus in Hematpoietic Stem Cell and Solid Organ Transplant Recipients

  Ison, M. G.

  National Institute of Allergy and Infectious Diseases

  7/1/16 → 6/30/21

  Project: Research project

  • nitazoxanide
  • Norovirus
  • Double-Blind Method
  • Transplant Recipients
  • Stem Cells

• Task Order 10, NU-Cost Reimbursable

  Ison, M. G.

  National Cancer Institute

  9/24/12 → 4/13/22

  Project: Research project

• Finished

  High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

  Ison, M. G.

  Vanderbilt University Medical Center, National Institute of Allergy and Infectious Diseases

  7/1/19 → 6/30/20

  Project: Research project

• High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients

  Ison, M. G.

  Vanderbilt University, National Institute of Allergy and Infectious Diseases

  7/5/17 → 6/30/19

  Project: Research project

  • Adult Stem Cells
  • Influenza Vaccines
  • Inactivated Vaccines
  • Transplant Recipients
  • Transplants

• Protocol 9766-CL-0111 - A Non-Interventional Registry Study of Systemic Antifungal Therapy in Adult Subjects with Invasive Mucormycosis or Invasive Aspergillosis Caused by a Non-fumigatus Species Protocol for Phase 4 Study of ASP9766

  Ison, M. G.

  inVentiv Health Clinical, Astellas Pharma Global Development, Inc.

  4/7/17 → 4/7/20

  Project: Research project

• Prot. CMV-01-16: Multi-Center Clinical Evaluation of the VERIS CMV Assay to Measure Cytomegalovirus (CMV) as an Aid in Monitoring Virologic Response to Therapy

  Ison, M. G.

  Beckman Coulter, Inc.

  12/4/16 → 12/4/19

  Project: Research project

• Prot #GS-US-218-1797: A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection

  Ison, M. G.

  PPD Development, Gilead Sciences, Inc.

  8/29/16 → 8/29/19

  Project: Research project

• Prot# US OI 124: The PROTECT Study: A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T cell-mediated Acute Graft Rejection

  Ison, M. G.

  Chiltern International, Inc., Oxford Immunotec, Inc.

  7/14/16 → 7/15/19

  Project: Research project

• Prot #63623872FLZ2002: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adolescent, Adult, and Elderly Hospitalized Patients W

  Ison, M. G.

  Janssen Research & Development, LLC

  1/19/16 → 8/31/18

  Project: Research project

• Protocol Number: IRC-005 A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

  Ison, M. G.

  Social & Scientific Systems, Inc., National Institute of Allergy and Infectious Diseases

  10/16/15 → 9/30/18

  Project: Research project

  • Human Influenza
  • Safety
  • Hemagglutination
  • Antiviral Agents
  • Transfusion-Related Acute Lung Injury

• Protocol IRC002 “A Randomized, Open-Label, Phase 2, Multicenter Safety and Exploratory Efficacy Study of Investigational anti-Influenza Immune Plasma for the Treatment of Influenza”

  Ison, M. G.

  Social & Scientific Systems, Inc., National Cancer Institute

  4/1/15 → 10/31/15

  Project: Research project

  • Human Influenza
  • Safety
  • Oseltamivir
  • Rimantadine
  • Mortality

• GS-US-218-0108, “A Phase 2b, Randomized, Double-Blind, A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) R

  Ison, M. G.

  Duke Clinical Research Institute, Gilead Sciences, Inc.

  3/24/15 → 3/24/18

  Project: Research project

• GS-US-218-1502, “A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial V

  Ison, M. G.

  Duke Clinical Research Institute, Gilead Sciences, Inc.

  3/24/15 → 3/24/18

  Project: Research project